Preview

Атеротромбоз

Расширенный поиск

ПРОФИЛАКТИКА ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ

https://doi.org/10.21518/2307-1109-2019-1-8-24

Полный текст:

Аннотация

Онкологическое заболевание является одним из самых значимых факторов риска развития венозных тромбоэмболических осложнений (ВТЭО). В статье рассматриваются современные положения медикаментозной тромбопрофилактики у различных групп пациентов с онкологическими заболеваниями.

Об авторе

Ю. А. Федоткина
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр кардиологии» Министерства здравоохранения
Россия

к.м.н., научный сотрудник отдела клинических проблем атеротромбоза

 тел.: (903) 711-62-39

121552, Россия, г. Москва, ул. 3-я Черепковская, д. 15а



Список литературы

1. Khorana A.A., Connolly G.C. Assessing risk of venous thromboembolism in the patient with cancer. Clin. Oncol. 2009;27:4839-4847.

2. Федоткина Ю.А., Панченко Е.П. Тромбозы в онкологии. Часть 2-я. Атеротромбоз. 2017;2:3-13.

3. Комаров А.Л. Клинический разбор пациента с рецидивирующими венозными тромбоэмболическими осложнениями. Атеротромбоз. 2017;(2):79-94. https://doi.org/10.21518/2307-1109-2017-2-79-94.

4. Blom J.U. et Al. The Hematologist modified from Biom. JAMA. 2005;293:715-722.

5. Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–8.

6. Hutten B.A., Prins M.H., Gent M. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078–83.

7. Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest.2012;141:e419S–94S.

8. Sahni V., Choudhury D., Ahmed Z. Chemotherapyassociated renal dysfunction. Nat Rev Nephrol. 2009;5:450–62.

9. Anderson F.A. Jr, Zayaruzny M., Heit J.A., Fidan D., Cohen A.T. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82:777-782.

10. Cohen A.T., Agnelli G., Anderson F.A. et al. Venous thromboembolism (VTE) in Europe: the number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756-764.

11. Raskob G.E., Angchaisuksiri P., Blanco A.N. et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34:2363-2371.

12. Lindblad B., Sternby N.H., Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ. 1991;302:709-711.

13. Sandler D.A., Martin J.F. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82:203-205.

14. Kucher N., Koo S., Quiroz R. et al. Electronic Alerts to Prevent Venou Thromboembolism among Hospitalized Patients. N Engl J Med. 2005;352:969-977.

15. Patell R., Rybicki L., McCrae K.R., Khorana A.A. Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool. American Journal of Hematology. 2017;92(6):501-507.

16. Samama M.M., Cohen A.T., Darmon J.Y. A Comparison of Enoxaparin with placebo for the prevention of thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:973-800. doi: 10.1056/NEJM199909093411103.

17. Leizorovicz A., Cohen A.T., Turpie A.G., Olsson C.G., Vaitkus P.T., Goldhaber S.Z. Randomized, placebocontrolled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-879.

18. Cohen A.T., Davidson B.L., Gallus A.S. et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325-329.

19. Rahn D.D., Mamik M.M., Sanses T.V. et al. Venous thromboembolism prophylaxis in gynecologic surgery:a systematic review. Obstet Gynecol. 2011 Nov;118(5):1111-25.

20. Vedovati M.C., Becattini C., Rondelly F. et Al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014;259(4):665-9.

21. Hull R.D., Schellong S.M., Tapson V.F. et al. Extendedduration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8-18.

22. Cohen A.T., Spiro T.E., Büller H.R. et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513-523.

23. Goldhaber S.Z., Leizorovicz A., Kakkar A.K. et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-2177.

24. Cohen A.T., Harrington R.A., Goldhaber S.Z. et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375:534–44.

25. Tao D.L., Bien J.Y., DeLoughery T.G., Shatzel J.J. Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis. Blood. 2017;129:653–5.

26. Merkow R.P., Bilimoria K.Y., McCarter M.D. et al. Postdischarge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011;254:131–7.

27. Agnelli G., Bolis G., Capussotti L. et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243:89–95.

28. Bergqvist D., Agnelli G., Cohen A.T. et al. ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975–80.

29. Rasmussen M.S., Jorgensen L.N., Wille-Jшrgensen P. et al. FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4:2384–90.

30. Lyman G.H., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophilaxis and treatment in patients with cancer; American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;1(17):2189-2204.

31. Kearon C., Akl E.A., Comerota A.J. et al. Antithrombotictherapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–496.

32. Kearon C., Akl E.A., Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.

33. Caplin D.M., Nikolic B., Kalva S.P. et al. Quality improvement guidelines for the performance of inferior vena cava filter placement for the prevention of pulmonary embolism. J Vasc Interv Radiol. 2011;22(11):1499–506.

34. Jaff M.R., McMurtry M.S., Archer S.L. et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–830.

35. Matsuo K., Carter C.M., Ahn E.H. et al. Inferior vena cava filter placement and risk of hematogenous distant metastasis in ovarian cancer. Am J Clin Oncol. 2013;36:362-67.

36. Farge D., Bounameaux H., Khorana A. et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452-66.

37. Khorana A.A., Otten H.M., Zwicker J.I., Connolly G.C., Bancel D.F., Pabinger I., the Subcommittee on H, Malignancy, Prevention of venous thromboembolismin cancer outpatients: guidance from the SSC of the ISTH. J. Thromb. Haemost. 2014;12(11):1928–1931.

38. Lyman G.H., Bohlke K., Khorana A.A., Kuderer N.M., Lee A.Y. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015;33:654–656.

39. Ay C., Dunkler D., Marosi C., Chiriac A.L. et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377–5382.

40. Moore R.A., Adel N., Riedel E., Bhutani M. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011;29:3466–3473.

41. Mandala M., Clerici M., Corradino I., Vitalini C. et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann. Oncol. 2012;23:1416–1421.

42. Khorana A.A., Kuderer N.M., Culakova E. Development and Validation of a predictive model for chemotherapyassociated thrombosis. Blood. 2008;111(10):4902-4907.

43. Maraveyas A., Waters J., Roy R., Fyfe D. et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur. J. Cancer. 2012;48:1283–1292.

44. Khorana A.A., Francis Ch.W., Kuderer N.M. et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thromb Res. 2017. http://dx.doi.org/10.1016/j.thromres.2017.01.009.

45. Agnelli G., Gussoni G., Bianchini C., Verso M. et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943–949.

46. Agnelli G., George D.J., Kakkar A.K. et al. W. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N. Engl. J. Med. 2012;366:601–609.

47. Streiff M.B., Holmstrom B., Ashrani A. et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J. Natl. Compr. Canc. Netw. 2015;13(9):1079–1095.

48. Santi R.M., Ceccarelli M., Catania G., Monagheddu C, et al. Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). Thromb. Res. 2016;140(Suppl. 1). http://dx.doi.org/10.1016/S0049-3848(16)30136-0.

49. Khorana A.A. Cancer and coagulation. Am. J. Hematol. 2012;87(Suppl. 1):S82–S87.

50. Verso M., Agnelli G., Barni S., Gasparini G., Labianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern. Emerg. Med. 2012;7(3):291–292.

51. George D., Agnelli G., Fisher W., Kakkar A. et al. Venous thromboembolism (VTE) prevention withsemuloparin in cancer patients initiating chemotherapy: benefit-risk assessmentby VTE risk in SAVE-ONCO. Blood. 2011. ASH Annual Meeting Program and Proceedings.

52. Levine M., Hirsh J., Gent M. et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886–9.

53. Khorana A.A., Soff G.A., Kakkar A.K., Vadhan-Raj S. et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019;380:720-8. doi: 10.1056/NEJMoa1814630.

54. Levine M.N., Gu C., Liebman H.A. et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012 May;10(5):807-14. doi: 10.1111/j.1538-7836.2012.04693.x.

55. Carrier M., Abou-Nassar K., Mallick R. et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019;380:711-9. doi: 10.1056/NEJMoa1814468.

56. Schulman S., Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-4.

57. Lyman G.H., Culakova E., Poniewierski M.S., Kuderer N.M. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164:Suppl 1:S112-S118.

58. Elting L.S., Escalante C.P., Cooksley C. et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164:1653-61.

59. Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-8.

60. Agnelli G. Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. N Engl J Med. 2019;380:781-3.


Для цитирования:


Федоткина Ю.А. ПРОФИЛАКТИКА ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ. Атеротромбоз. 2019;(1):8-24. https://doi.org/10.21518/2307-1109-2019-1-8-24

For citation:


Fedotkina J.A. PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH CANCER. Atherothrombosis. 2019;(1):8-24. (In Russ.) https://doi.org/10.21518/2307-1109-2019-1-8-24

Просмотров: 205


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)